eTheRNA
Cambridge, United States· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Total funding raised: $39M
Overview
An mRNA technology company developing novel vaccines and immunotherapies using its proprietary LNP delivery platform.
Infectious DiseaseOncology
Technology Platform
A proprietary mRNA and lipid nanoparticle (LNP) platform designed to optimize immunogenicity and delivery for vaccines and therapies.
Funding History
1Total raised:$39M
IPO$39M
Opportunities
Growing demand for mRNA technology in new therapeutic areas beyond COVID-19 vaccines presents significant partnership and licensing potential.
Risk Factors
Intense competition and high capital requirements in the mRNA space, with risk of being outpaced by larger players.
Competitive Landscape
Competes in the highly active mRNA sector, requiring clear differentiation from established leaders through its delivery technology.